Efficacy and Safety of Rifaximin-α in Treating MASLD

Clinical trial NCT07381257 · RECRUITING

Trial details

NCT number: NCT07381257
Sponsor: Shanghai Changzheng Hospital
Status: RECRUITING
Phase: Early Phase 1
Study type: INTERVENTIONAL

Metabolic Dysfunction-Associated Steatotic Liver Disease

Start date: 2026-01-15
Primary completion: 2027-12-31
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.